Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Takeda
The drug being tested in this study is called Vonoprazan (Takecab). Vonoprazan is being tested to treat people who have gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, stomach following endoscopic treatment of early gastric cancer, or H. pylori gastritis. This study will look at the presence or absence of new concerns regarding the safety of triple therapy with Vonoprazan tablets, amoxicillin, and clarithromycin (first-line eradication) and triple therapy with Vonoprazan tablets, amoxicillin, and metronidazole (second-line eradication) for supplemental Helicobacter pylori (H. pylori) eradication in the routine clinical setting. The study will enroll approximately 500 patients.
First-line eradication
* Vonoprazan 20 mg / Proton pump inhibitor
* Amoxicillin hydrate 750 mg
* Clarithromycin 200 mg
If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful.
Second-line eradication
* Vonoprazan 20 mg
* Amoxicillin hydrate 750 mg
* metronidazole 250 mg
This multi-center trial will be conducted in Japan.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants receiving H. pylori eradication treatment for the first time
Participants for whom H. pylori eradication with Takecab tablets or proton pump inhibitor + amoxicillin + clarithromycin was found unsuccessful and who will receive eradication treatment with amoxicillin and metronidazole
You may not be if
Participants with previous history of hypersensitivity to ingredients in Takecab tablets
Participants taking atazanavir sulfate or rilpivirine hydrochloride